(LFMD) LifeMD - Ratings and Ratios

LifeMD, Inc. (NASDAQ:LFMD) is a direct-to-patient telehealth company specializing in virtual medical care and digital health solutions. The company operates a diverse portfolio of telehealth brands, including RexMD, ShapiroMD, NavaMD, and Cleared, each addressing specific health needs. RexMD focuses on mens health, offering virtual consultations and treatments for conditions such as erectile dysfunction, hair loss, and other mens health issues. ShapiroMD extends into male and female hair loss solutions, providing prescription medications, patented OTC products, and compounded topical treatments. NavaMD targets female-oriented tele-dermatology, offering virtual consultations for aging, acne, and other skin-related concerns. Cleared provides personalized allergy, asthma, and immunology treatments, including in-home allergy tests and immunotherapies.

LifeMD also offers LifeMD PC, a direct-to-consumer virtual primary care service that includes 24/7 access to providers for primary, urgent, and chronic care needs. Additional services include virtual consultations, prescription medications, diagnostics, and wellness coaching. Beyond its telehealth offerings, the company operates a suite of SaaS platforms, including PDFSimpli for PDF management, ResumeBuild for digital resume and cover letter services, SignSimpli for digital signatures, and LegalSimpli for legal forms. These tools cater to both consumers and small businesses, enhancing productivity and convenience.

LifeMD distributes its products and services directly to consumers through its e-commerce platforms and third-party partner channels. Formerly known as Conversion Labs, Inc., the company rebranded as LifeMD, Inc. in February 2021 to reflect its focus on healthcare and telemedicine. Incorporated in 1994, LifeMD is headquartered in New York, New York, and operates under the ticker symbol LFMD on the NASDAQ exchange. Its market capitalization is approximately $217.49 million, with a forward P/E ratio of 22.42 and a price-to-book ratio of 107.72.

3-Month Forecast: Based on the provided data, LifeMDs stock price has been trending below its SMA 20 and SMA 50, indicating near-term weakness. However, the forward P/E of 22.42 suggests investor confidence in future earnings growth. With an ATR of $0.51, volatility is moderate, and the stock may consolidate in the $5-$6 range. The companys high RoE of 301.60 indicates strong profitability, which could support a bullish case if maintained. Overall, the stock is likely to remain range-bound in the short term, with potential upside if the company demonstrates revenue growth or improved margins.